Last reviewed · How we verify
Vabomere
At a glance
| Generic name | Vabomere |
|---|---|
| Also known as | Combination meropenem and vaborbactam, beta-lactamase inhibitor and carbapenem antibiotic, carbapenem and beta-lactamase inhibitor |
| Sponsor | Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis (PHASE2)
- Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections (PHASE1)
- Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults (PHASE3)
- Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers (PHASE1)
- Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vabomere CI brief — competitive landscape report
- Vabomere updates RSS · CI watch RSS
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) portfolio CI